Amantadine for Parkinson's disease.
D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D000588:Amines / Q000134:cerebrospinal fluid / Q000652:urine; D001921:Brain / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004185:Disability Evaluation; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009135:Muscular Diseases / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010919:Placebos; D014202:Tremor / Q000188:drug therapy
D000588:Amines; D010919:Placebos; D004295:Dihydroxyphenylalanine; D000547:Amantadine